Lung cancers bearing the oncogenic receptor tyrosine kinases (RTKs), EGFR, ALK, and ROS1, are amenable to precision oncology treatments with distinct tyrosine kinase inhibitors (TKIs) that provide superior tumor regression, progression-free survival, overall survival, and quality of life compared to standard chemotherapy1–6. This evidence concerns the gene ALK and lung carcinoma.